AstraZeneca PLC (AZN)vsKrystal Biotech Inc (KRYS)
AZN
AstraZeneca PLC
$185.95
+0.83%
HEALTHCARE · Cap: $282.69B
KRYS
Krystal Biotech Inc
$343.43
-2.21%
HEALTHCARE · Cap: $9.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 14383% more annual revenue ($60.44B vs $417.30M). KRYS leads profitability with a 53.9% profit margin vs 17.2%. AZN trades at a lower P/E of 27.5x. KRYS earns a higher WallStSmart Score of 65/100 (C+).
AZN
Buy64
out of 100
Grade: C+
KRYS
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Intrinsic value data unavailable for KRYS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Keeps 54 of every $100 in revenue as profit
Strong operational efficiency at 46.1%
Revenue surging 31.9% year-over-year
Earnings expanding 52.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 53.9% and operating margin at 46.1%. Revenue growth of 31.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio. A P/E of 42.6x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while KRYS is a growth play — different risk/reward profiles.
KRYS carries more volatility with a beta of 0.53 — expect wider price swings.
KRYS is growing revenue faster at 31.9% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (65/100 vs 64/100), backed by strong 53.9% margins and 31.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?